Retail investors tracking the digital health sector are watching closely as chronic disease management becomes a priority for employers and insurers alike. DarioHealth Corp. (DRIO:NASDAQ) recently announced a new agreement with a major health insurer with a stronghold in Arizona through its strategic channel partnership with Amwell. This development positions the company within a fast-growing market where remote monitoring and behavior-driven care are in high demand.
Digital Health Market Expands on Chronic Care Demand
According to a May report from Grand View Research, the global digital health market was valued at US$347.4 billion in 2025 and was estimated to reach US$420.2 billion in 2026. North America accounted for 37.1% of global revenue in 2025, supported by a strong domestic digital health market for telehealthcare platform developers, mHealth app providers, wearable device manufacturers, and e-prescription systems.
The rising incidence of chronic conditions such as diabetes, heart disease, and cancer is fueling the demand for remote monitoring and management solutions. Diabetes represented the largest application segment, accounting for more than 25% of market share in 2025, while telehealth held the largest technology segment with a 44.7% market share.
Writing on July 6, Market.us Media reported that the global home healthcare market was valued at US$420.8 billion in 2024 and was projected to reach approximately US$900.1 billion by 2034, reflecting a 7.9% compound annual growth rate. Advances in digital health technologies, including remote patient monitoring and telehealth, have further enhanced the quality and accessibility of home-based care.
New Arizona Agreement Highlights Channel Strategy Strength
The recent agreement makes Dario's cardiometabolic solution available to the insurer's Administrative Services Only (ASO) book of business, representing access to hundreds of thousands of covered lives. The solution will be positioned within the insurer's ASO portfolio for employer clients seeking to address diabetes, hypertension, and weight management through a unified, behaviorally driven approach. Employers can adopt the solution based on their specific population needs and benefits strategy, with tailored deployments at scale.
This agreement demonstrates how the company's channel strategy is driving scalable, efficient access to large employer populations. By leveraging channel partner infrastructure and relationships, Dario can rapidly reach a high-value ASO population and embed its platform within the health plan ecosystem. The partnership with Amwell supports a capital-efficient growth model by lowering customer acquisition costs, accelerating sales cycles, and supporting expansion across employer populations. Dario now has access to more than 116 million covered lives through its expanding channel partnership network.
Key Investor Takeaways
- DarioHealth's new Arizona insurer agreement provides immediate access to hundreds of thousands of covered lives through an established ASO channel.
- The cardiometabolic platform has demonstrated up to five times return on investment for employers in a Sanofi-funded study backed by more than 100 scientific publications.
- Channel partnerships such as Amwell reduce acquisition costs and accelerate sales while expanding reach to over 116 million covered lives.
- Analysts at Stifel and CG Capital maintain positive ratings with price targets of US$7.28 and US$28.00, respectively, citing commercial execution and platform consolidation.
- The company addresses multiple chronic conditions on a single AI-powered platform, improving retention and engagement metrics for enterprise clients.
- Market tailwinds from rising chronic disease prevalence and home healthcare growth support long-term adoption of remote monitoring solutions.
Platform Delivers Measurable Outcomes for Employers
According to the company, Dario's solution delivers up to five times return on investment to employers, as demonstrated in a study funded by Sanofi and supported by more than 100 scientific studies, including peer-reviewed journal publications and conference abstracts.
Savings for clients are generated through fewer hospitalizations and improvements in metrics, including systolic blood pressure, A1C, and hyperglycemic events. Early DarioIQ results showed up to a 40% improvement in member retention and up to a 57% increase in active sessions compared with a control group.
Streetwise Ownership Overview*
DarioHealth Corp. (DRIO:NASDAQ)
| Date | Old Symbol | Old Shares | New Symbol | New Shares |
|---|---|---|---|---|
| 11/18/19 | DRIO | 20 | DRIO | 1 |
| 03/20/13 | LSYI | 1 | DRIO | 1 |
Analyst Views Focus on Commercial Momentum
In a July 5 weekly digital health report, David M. Grossman of Stifel wrote that the Stifel Digital Health Index gained 11% during the week, outperforming the Bloomberg 2000 Growth Index, which was flat. The digital health index had outperformed the broader growth benchmark by 3,700 basis points over the previous 90 days. Stifel highlighted DarioHealth's recent announcements, including an expanded relationship with a national health plan and a strategic collaboration with Beluga Health, and maintained a Buy rating with a US$7.28 price target.
Earlier research from CG Capital also maintained an Outperform rating and US$28.00 price target on DarioHealth, citing sequential revenue growth, operating expense discipline, and implementation of enterprise client wins.
Share Structure and Ownership Snapshot
DarioHealth Corp. has a market cap of US$51.41 million, with 7.3 million shares outstanding. The company's 52-week range is US$5.84-US$17.74.
1Institutions own 39.4% of shares, while Strategic Investors own 7.5%. Management & Insiders own 4.5% of shares, and the remaining 48.6% of shares are held by Retail.
Common Questions from Investors
- What is the new agreement's reach? It provides Dario's cardiometabolic solution to hundreds of thousands of covered lives through a major Arizona health insurer's ASO book.
- How does the company achieve capital-efficient growth? Channel partnerships like Amwell lower acquisition costs and accelerate sales cycles while expanding access to over 116 million lives.
- What evidence supports the platform's ROI? A Sanofi-funded study and more than 100 scientific publications show up to five times return on investment through reduced hospitalizations and improved health metrics.
- Which analysts cover the stock? Stifel maintains a Buy rating with a US$7.28 target, while CG Capital holds an Outperform rating and US$28.00 target.
According to the company's May 2026 corporate presentation, Dario's commercial strategy includes working across employers, health plans, and channel partners. The presentation states that the company intends to continue leveraging broker and consultant relationships, expand engagement with health plans, including pharmacy benefit managers and third-party administrators, and continue working with delivery partners while evaluating additional channel partnerships.
The presentation also outlines initiatives to expand product reach by adding conditions to increase eligible populations and covered lives, improving technology to increase enrollment rates, and adding new condition partners. It further describes efforts to improve enrollment and engagement through technology enhancements and the addition of claims-based data and analytics.
| Want to be the first to know about interesting Gold investment ideas? Sign up to receive the FREE Streetwise Reports' newsletter. | Subscribe |
Important Disclosures:
- DarioHealth Corp. is a billboard sponsor of Streetwise Reports and pays SWR a monthly sponsorship fee between US$3,000 and US$6,000.
- Jordan Nova wrote this article for Streetwise Reports LLC and provides services to Streetwise Reports as an employee.
- This article does not constitute investment advice and is not a solicitation for any investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Each reader is encouraged to consult with his or her personal financial adviser and perform their own comprehensive investment research. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company.
For additional disclosures, please click here.
1. Ownership and Share Structure Information
The information listed above was updated on the date this article was published and was compiled from information from the company and various other data providers.
